Buscador de publicacions

Publicacions

  • Río P, Navarro S, Wang W, Sánchez-Domínguez R, Pujol RM, Segovia JC, Bogliolo M, Merino E, Wu N, Salgado R, Lamana ML, Yañez RM, Casado JA, Giménez Y, Román-Rodríguez FJ, Álvarez L, Alberquilla O, Raimbault A, Guenechea G, Lozano ML, Cerrato L, Hernando M, Gálvez E, Hladun R, Giralt I, Barquinero J, Galy A, García de Andoín N, López R, Català-Temprano A, Schwartz JD, Surrallés J, Soulier J, Schmidt M, Díaz de Heredia C, Sevilla J and Bueren JA.

    Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia.

    NATURE MEDICINE . 25(9): 1396-1401. Nº de cites: 93

    [doi:10.1038/s41591-019-0550-z]

  • Revilla N, Corral J, Miñano A, Mingot-Castellano ME, Campos RM, Velasco F, Gonzalez N, Galvez E, Berrueco R, Fuentes I, Gonzalez-Lopez TJ, de la Morena-Barrio ME, Gonzalez-Porras JR, Vicente V and Lozano ML.

    Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content

    Platelets . 30(6): 743-751. Nº de cites: 44

    [doi:10.1080/09537104.2018.1513476]

  • Monteagudo E, Astigarraga I, Cervera Á, Dasí MA, Sastre A, Berrueco R and Dapena JL.

    Protocol for the study and treatment of primary immune thrombocytopenia: ITP-2018

    ANALES DE PEDIATRIA . 91(2): . Nº de cites: 3

    [doi:10.1016/j.anpede.2019.04.008]

  • Gassiot S, González Y, Morgades M, Motlló C, Clapés V, Maluquer C, Ibarra G, Abril L, Ribera JM and Oriol A.

    Response to first cycle is the major predictor of long term response to lenalidomide and dexamethasone therapy in relapsed and refractory multiple myeloma: can we spare patients the toxicity and costs of additional agents?

    Clinical Lymphoma, Myeloma and Leukemia . : . Nº de cites: 1

    [doi:10.1016/j.clml.2019.05.020]

  • Sánchez-Martínez D, Baroni ML, Gutierrez-Agüera F, Roca-Ho H, Blanch-Lombarte O, González-García S, Torrebadell-Burriel M, Junca J, Ramírez-Orellana M, Velasco-Hernández T, Bueno C, Fuster JL, Prado JG, Calvo J, Uzan B, Cools J, Camós-Guijosa M, Pflumio F, Toribio ML and Menéndez P.

    Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.

    Blood . 133(21): 2291-2304. Nº de cites: 73

    [doi:10.1182/blood-2018-10-882944]

  • Martinez-Monseny T, Bolasell M, Callejón L, Cuadras-Palleja D, Freniche V, Itzep DC, Gassiot S, Arango P, Casas-Alba D, de la Morena E, Corral J, Montero-Sanchez R, Pérez-Cerdá C, Pérez-Dueñas B, Artuch-Iriberri R, Jaeken J, and the CDG Spanish Consortium and Serrano M.

    AZATAX: Acetazolamide safety and efficacy in cerebellar syndrome in PMM2 congenital disorder of glycosylation (PMM2-CDG)

    ANNALS OF NEUROLOGY . 85(5): 740-751. Nº de cites: 46

    [doi:10.1002/ana.25457]

  • Arias-Salgado EG, Galvez E, Planas-Cerezales L, Pintado-Berninches L, Vallespin E, Martinez P, Carrillo J, Iarriccio L, Ruiz-Llobet A, Català-Temprano A, Badell-Serra I, Gonzalez-Granado LI, Martín-Nalda A, Martínez-Gallo M, Galera-Miñarro A, Rodríguez-Vigil C, Bastos-Oreiro M, Perez de Nanclares G, Leiro-Fernández V, Uria ML, Diaz-Heredia C, Valenzuela C, Martín S, López-Muñiz B, Lapunzina P, Sevilla J, Molina-Molina M, Perona R and Sastre L.

    Genetic analyses of aplastic anemia and idiopathic pulmonary fibrosis patients with short telomeres, possible implication of DNA-repair genes.

    ORPHANET JOURNAL OF RARE DISEASES . 14(1): 82-82. Nº de cites: 17

    [doi:10.1186/s13023-019-1046-0]

  • Castella M, Boronat A, Martín-Ibáñez R, Rodríguez V, Suñé G, Caballero M, Marzal B, Pérez-Amill L, Martín-Antonio B, Castaño J, Bueno C, Balagué O, González-Navarro EA, Serra-Pages C, Engel P, Vilella R, Benitez-Ribas D, Ortiz-Maldonado V, Jordi Cid Colom, Tabera J, Canals JM, Lozano M, Baumann T, Vilarrodona A, Trias E, ELENA CAMPO, Menendez P, Urbano-Ispizua Á, Yagüe-Ribes J, Pérez-Galán P, Rives-Solà S, Delgado J and Juan M.

    Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions.

    Molecular Therapy-Methods & Clinical Development . 12: 134-144. Nº de cites: 59

    [doi:10.1016/j.omtm.2018.11.010]

  • Borràs N, Orriols G, Batlle J, Pérez-Rodríguez A, Fidalgo T, Martinho P, López-Fernández MF, Rodríguez-Trillo Á, Lourés E, Parra R, Altisent C, Cid AR, Bonanad S, Cabrera N, Moret A, Mingot-Castellano ME, Navarro N, Pérez-Montes R, Marcellini S, Moreto A, Herrero S, Soto I, Fernández-Mosteirín N, Jiménez-Yuste V, Alonso N, de Andrés-Jacob A, Fontanes E, Campos R, Paloma MJ, Bermejo N, Berrueco R, Mateo J, Arribalzaga K, Marco P, Palomo Á, Castro Quismondo N, Iñigo B, Nieto MDM, Vidal R, Martínez MP, Aguinaco R, Tenorio JM, Ferreiro M, García-Frade J, Rodríguez-Huerta AM, Cuesta J, Rodríguez-González R, García-Candel F, Dobón M, Aguilar C, Vidal F and Corrales I.

    Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA

    HAEMATOLOGICA . 104(3): 587-598. Nº de cites: 11

    [doi:10.3324/haematol.2018.203166]

  • Pascual-Pastó G, Bazan-Peregrino M, Gene-Olaciregui N, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa MG, Paco-Mercader S, Vilà-Ubach M, Cuadrado-Vilanova M, Castillo H, Botteri G, García-Gerique L, Moreno-Gilabert H, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torrebadell-Burriel M, Roldan-Molina M, König A, Suñol M, Claverol J, Lavarino C, de Torres C, Fu L, Radvanyi F, Munier FL, Català-Mora J, Mora J, Alemany R, Cascallo M, Chantada G and Carcaboso AM.

    Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01

    SCIENCE TRANSLATIONAL MEDICINE . 11(476): 9321. Nº de cites: 63

    [doi:10.1126/scitranslmed.aat9321]